Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lack of N1L gene expression results in a significant decrease of vaccinia virus replication in mouse brain.

B Billings1, S A Smith, Z Zhang

  • 1Department of Microbiology and Immunology, University of Louisville School of Medicine, Kentucky 40202, USA.

Annals of the New York Academy of Sciences
|January 22, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugs.

Molecular psychiatry·2019
Same author

Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism.

Molecular psychiatry·2016
Same author

Abnormal cerebrospinal fluid (CSF) dynamics in Alzheimer's disease and normal pressure hydrocephalus: CSF-amyloid β precursor protein metabolites as possible biomarkers.

European journal of neurology·2012
Same author

Epigenetics: a paradigm shift in understanding Alzheimer's disease.

Current Alzheimer research·2012
Same author

Current drug targets for modulating Alzheimer's amyloid precursor protein: role of specific micro-RNA species.

Current medicinal chemistry·2011
Same author

The "aged garlic extract:" (AGE) and one of its active ingredients S-allyl-L-cysteine (SAC) as potential preventive and therapeutic agents for Alzheimer's disease (AD).

Current medicinal chemistry·2011

A vaccinia virus protein (13.8 kDa) enhances viral replication in the brain. A modified virus lacking this protein (vGK5) is attenuated, safe, and shows potential as a live vaccine candidate.

Area of Science:

  • Virology
  • Immunology
  • Neuroscience

Background:

  • Vaccinia virus produces secretory proteins called virokines.
  • The N1L open reading frame encodes a major 13.8 kDa virokine.
  • Recombinant vaccinia virus vGK5, lacking the 13.8 kDa protein, exhibits significant in vivo attenuation.

Purpose of the Study:

  • To investigate the role of the 13.8 kDa vaccinia virus protein in viral replication and pathogenesis within the brain.
  • To evaluate the potential of the attenuated vGK5 virus as a live vaccine candidate for brain infections.

Main Methods:

  • Generation of a recombinant vaccinia virus (vGK5) lacking the N1L-encoded 13.8 kDa protein.
  • Intracranial injection of wild-type vaccinia virus and vGK5 into mice.
  • Analysis of viral replication, brain histology, neutrophil infiltration, and nitric oxide synthase activity.

Related Experiment Videos

Main Results:

  • The 13.8 kDa protein significantly enhances vaccinia virus replication in brain tissue.
  • vGK5 exhibits poor replication in the brain, diminishing the risk of postvaccinial encephalitis.
  • Mice vaccinated with vGK5 developed resistance to lethal vaccinia virus challenge, indicating immunogenicity without virulence.

Conclusions:

  • The 13.8 kDa vaccinia virus protein is crucial for efficient viral replication in the brain.
  • vGK5 represents a promising vaccine candidate due to its attenuation, immunogenicity, and reduced neurovirulence.
  • vGK5 can induce protective immunity in the brain while minimizing the risk of severe side effects.